Understanding prostate cancer through urine analysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to identify new biomarkers for significant prostate cancer by analyzing urine metabolomics. It involves a prospective, observational approach with three cohorts: a training cohort to develop predictive models, a validation cohort to test these models, and a control cohort. The study will enroll 620 men and 20 women, focusing on those undergoing prostate biopsy or who have recently completed one. The goal is to improve screening and reduce overtreatment of insignificant prostate cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subjects who have planned to undergo prostate biopsy or have completed biopsy before 6 weeks.
2. Subjects who are aged between 30 and 100 years men.
3. For subjects who are prostate cancer patients for rebiopsy, the testosterone level should be within normal limit (testosterone \>1.5 ng/ml).
4. Subjects who understand the entire study procedures and consent to donate his spot urine (once for 50 ml) and agree with subsequent analyses of his clinical information including biopsy results, treatments and outcomes. (Note: Subjects will be told that the urine metabolomics results will not be revealed to them.)

Exclusion Criteria:

1. Subjects who have other active cancers. However, subjects who have cancers that have been curatively treated and who are disease-free for 3 years or longer are allowed to be enrolled.
2. Subjects who have severe organ function impairment which may significantly alter general cell metabolism determined by the investigators, such as or Cre \> 3.0, HbA1c \> 9.0%, symptomatic heart failure, or other symptomatic metabolic diseases.
3. Subjects who are receiving or have received systemic therapy, such as chemotherapy, androgen deprivation therapy (ADT), immunotherapy, or targeted therapy within 3 months of the screening.
4. Subjects who have been treated with pelvic radiotherapy within 3 months of the screening.
5. Subjects who have significant infection or inflammation within 8 weeks of the biopsy.
6. Subjects who have pyuria (defined as \> 5 WBC/HPF) of urinalysis results within 4 weeks of the biopsy
7. Topical or oral prednisolone equivalent dosage larger 10 mg per day for 14 days or more.
8. The last dose of prednisolone is within 4 weeks of the biopsy.
9. Subjects who have a life expectancy less than 12 months.
10. Subjects who use MCS or found supplementation containing large amount of lycopene in recent 60 days or less. The definition of large amount of lycopene is more than 2 mg per day.

Where it's running

• Department of Urology, National Taiwan University Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: Yeong-Shiau Pu, MD PhD — Department of Urology, National Taiwan University Hospital
• Study coordinator: Chung-Hsin Chen, MD PhD
• Email: mufasachen@gmail.com
• Phone: +886-23123456

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Transperineal vs Transrectal Cognitive Fusion Biopsy for Prostate Cancer

  This study tests whether a transperineal cognitive fusion biopsy works as well as the traditional transrectal approach for detecting clinically significant prostate cancer in men with suspicious mpMRI findings.

  Recruiting Ankara Etlik City Hospital · Ankara, Yenimahalle · NCT07710807

• Multi-Modal Imaging and Digital Pathology to Predict Clinically Significant Prostate Cancer

  A multi-center study tests a deep learning model that combines MRI, ultrasound, and digital pathology to see if it can predict clinically significant prostate cancer non-invasively and help guide biopsies.

  Recruiting Guangxi Medical University · Liuzhou, Guangxi · NCT07614256

• Blood exosomal RNA test to diagnose clinically significant prostate cancer

  This study will test whether a blood-based exosome RNA signature can detect clinically significant prostate cancer in men with elevated PSA and suspicion for cancer.

  Recruiting at 10 sites Xijing Hospital · Chicago, Illinois and 9 other locations · NCT07492927

• Using PSMA PET/CT imaging to help choose which men with low-risk prostate cancer can enter active surveillance

  The team will test whether delayed Ga-68 PSMA PET/CT scans using the Istanbul PSMA PET/CT Criteria can help decide which men with biopsy-confirmed low-risk prostate cancer can safely choose active surveillance.

  Recruiting at 10 sites Istanbul University - Cerrahpasa · Istanbul, Turkey and 9 other locations · NCT07168616

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.